Sinuses bothering you? Use those nasal sprays regularly
UC expert says proper use of nasal spray ‘dramatically’ lessens need for antibiotics
Nasal saline and corticosteroid sprays are pretty standard treatment for individuals battling chronic rhinosinusitis (CRS). They thin out thick mucus buildup and help ease the swelling in the nasal cavity that are the bane of anyone who has battled what physicians often refer to as the asthma of the sinuses.
If used consistently and appropriately, these nasal sprays can lessen the need for antibiotics and oral steroids that are needed when symptom severities flare, according to a recent study from Dr. Ahmad Sedaghat, an ear, nose and throat specialist at the University of Cincinnati College of Medicine.
Sedaghat and a team of researchers looked at 150 patients at Massachusetts Eye and Ear undergoing medical management for CRS and found that CRS-related usage of oral steroids and antibiotics dropped by 0.2 courses per three-month period on average. That’s about one fewer courses of antibiotics and oral steroids in a year to deal with severe symptoms of CRS.
Those results were reported in the scholarly journal Laryngoscope and, according to researchers, are statistically significant.
When researchers focused on individuals in this study needing oral steroids (roughly 40 patients) and those needing antibiotics (33 patients), the use of antibiotics for CRS dropped by 40% while the use of oral steroids associated with CRS decreased by 67%, said Sedaghat.
“We found that the use of the sprays or irrigations improved antibiotics and oral steroids usage by closer to three-to-four courses per year, on average, which is a huge effect,” said Sedaghat, also a UC Health physician. “Medication usage was reduced by one course every three-to-four months. The medical therapy we provided in the form of intranasal saline and intranasal steroids dramatically cut down on the usage of systemic antibiotics and steroids.”
Antibiotics have gastric and intestinal side effects and lead to body resistance, while long-term use of steroids can cause mood disturbance, insomnia, weight gain, diabetes, cataracts and other problems. “We really want to minimize the use of these medications,” said Sedaghat.
“If you simply treat patients regularly and consistently with what we call appropriate medical management, and that means staying on top of them and making sure these patients are using their sprays every single day, these patients will have dramatically fewer problems,” said Sedaghat.
CRS is similar to asthma, but it occurs in the sinuses instead of the lungs.
“Most people know someone who has asthma,” he said. “In those individuals, the body produces inflammation in the lining of the lungs, and that leads to wheezing and chest tightening and shortness of breath. In some people, the body produces inflammation in the lining of the sinuses. It’s not fatal like asthma, but chronic rhinosinusitis leads to a dramatic decrease in the quality of life. They are miserable.”
There are four main symptoms of CRS — nasal obstruction, nasal drainage, facial pain or pressure and decreased sense of smell. Patients need to have two out of four of these symptoms for at least 12 weeks to be diagnosed with CRS.
“The hope is with the consistent use of these nasal irrigations and corticosteroid sprays, we can keep symptoms at an acceptable level and so symptoms don’t affect patients’ quality of life,” said Sedaghat.
Sedaghat said researchers initially believed that individuals who came into the study with more severe CRS symptoms would need more antibiotics or steroids. “What we found is that is not the case,” he said. “What we found is the usage of antibiotics and steroids and the acute exacerbations is independent of baseline symptomlogy.”
“How bad you are on a day-to-day basis, that behavior of the disease, is very different than the frequency of you getting exacerbations in symptoms. These spikes in symptoms are coming from somewhere else,” said Sedaghat. “If physicians are not savvy to this, you may see someone with low-level symptoms and think the patient will be fine and believe treatment shouldn’t be as rigorous. In those patients, we found exacerbations of symptoms.”
“The frequency you needed antibiotics before the study is predictive of the frequency you need antibiotics at the end of the study,” said Sedaghat. “If you needed more antibiotics when you first started, then you will need antibiotics during the study period even if the frequency of exacerbations decreased.”
Other study co-authors include Lloyd Hoehle, Dr. David Caradonna and Dr. Stacey Gray, all three from Harvard Medical School in Boston; Dr. Marlene Speth from Kantonsspital Aarau in Aarau Switzerland; and Dr. Katie Phillips from Stanford University. No conflicts of interest were reported with this study.
Innovators lead the way at UC
The University of Cincinnati's College of Medicine is ranked by U.S. News and World Report among the top 40 medical schools in the area of research. UC's faculty and students investigate problems and innovate solutions with real-world impact as part of our strategic direction, Next Lives Here.
UC startups recognized by Cincy Inno for commitment to innovation
June 7, 2023
The University of Cincinnati's entrepreneurial spirit is once again front and center. In a recent Business Courier article touting the finalists in an awards competition by Cincy Inno, 20% were UC-affiliated startups.
WVXU: Researchers look to variations of psychedelic drugs as the...
June 6, 2023
Eric Wohleb of the UC Department of Pharmacology and Systems Physiology in the College of Medicine is collaborating with a researcher at Miami University to explore the use of magic mushrooms as treatments for a variety of mental health conditions. WVXU produced a story on the efforts.
Pioneering treatments for ‘brain tsunamis’
June 5, 2023
University of Cincinnati researchers have enrolled the first four patients in a first-of-its-kind trial that will test a treatment for abnormal brain activity sometimes referred to as a “brain tsunami.”